Safety, Pharmacokinetics, and Pharmacodynamics of a First‐in‐Class ClC‐1 Inhibitor to Enhance Muscle Excitability: Phase I Randomized Controlled Trial
Sign Up to like & getrecommendations! Published in 2024 at "Clinical Pharmacology and Therapeutics"
DOI: 10.1002/cpt.3516
Abstract: NMD670 is a first‐in‐class inhibitor of skeletal muscle‐specific chloride channel ClC‐1, developed to improve muscle weakness and fatigue in neuromuscular diseases. Preclinical studies show that ClC‐1 inhibition enhances muscle excitability, improving muscle contractility and strength.… read more here.
Keywords: first class; muscle excitability; muscle; pharmacokinetics pharmacodynamics ... See more keywords